The number of pharmaceutical representatives of 30 Japanese companies ranks in 2021, the number of pharmaceutical representatives continues to decrease

The number of medical representatives continues to decrease!

This week, the latest issue of the Medical Information Express magazine released a survey on the number of pharmaceutical representatives of Japanese companies in 2021.

Every year, the friends who pay attention to the sharing of content related to the theme of Dami should have the impression that in the survey of Japanese pharmaceutical companies in 2019 and 2020, the number of people who have been reduced by more than 2,000 for two consecutive years, although the number of survey results this year has changed Fewer, but the trend of fewer employees continues

The reduction is based on 54 Japanese pharmaceutical companies that can be compared with the previous year’s survey.

Therefore, the total number of people reduced will not be less than the number of 1007!

Companies with actual reductions of more than 100 people include Shionoyoshi Pharmaceutical (reduction of 150 people), Eli Lilly Japan (reduction of 100 people), and Merck (reduction of 100 people)

Due to the epidemic, in the past year, Japanese companies have re-evaluated and defined the behavior and role of medical representatives, including transforming to online + offline integrated activities, etc.

However, for the reasons for the decrease in the number of medical representatives, most companies said they would optimize their organization according to the market environment and product pipeline

Therefore, according to the judgment of the Japanese industry, in addition to the changes in the number of medical representatives caused by the epidemic, the severe new drug market environment in recent years and the trend of new drug development have also affected the allocation of the number of medical representatives

Of course, in the past year, there have been companies that have increased the number of medical representatives, but they are basically more than 20 people, such as Xinglin Pharmaceutical, Otsuka Pharmaceutical, and Towa Pharmaceuticals.

Many people in the Japanese industry believe that the most fundamental reason for the accelerated decrease in the number of pharmaceutical representatives in Japanese pharmaceutical companies in recent years is the thorough reform of the drug price system that began in 2018.

The changes in medical policies will indeed affect the employment environment to a large extent.